HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Money

Alphabet's AI biotech Isomorphic Labs bags $2.1B series B to fuel next-gen drug design model

If any proof was needed that big money is still available for AI drug development, look no further than the 10-figure series B hauled in by Isomorphic Labs.

By FierceBiotech · May 13, 2026 · via FierceBiotech
Alphabet's AI biotech Isomorphic Labs bags $2.1B series B to fuel next-gen drug design model

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

Tags
moneyformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Money
All Money →
CSL slashes revenue projection and takes $5B impairment as interim CEO flags R&D misses, market erosion
MoneyFiercePharma ↗
CSL slashes revenue projection and takes $5B impairment as interim CEO flags R&D misses, market erosion
CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another ind…
May 12, 2026
Odyssey’s CEO sees $304M IPO as chance to create a ‘little large pharma’
MoneyFierceBiotech ↗
Odyssey’s CEO sees $304M IPO as chance to create a ‘little large pharma’
Odyssey Therapeutics has become the latest biotech to voyage to the public markets via an upsized $304 million…
May 11, 2026
Daiichi Sankyo takes $610M profit hit linked to ADC manufacturing overbuild
MoneyFiercePharma ↗
Daiichi Sankyo takes $610M profit hit linked to ADC manufacturing overbuild
Daiichi Sankyo is poised to report significantly lower full-year profit for fiscal year 2025, primarily due to…
May 11, 2026